TET2 and acute myeloid leukemia: We observed the same patterns of increased or decreased DNAm when we compared AML patients with DNMT3A or TET2 mutations to AML patients with other mutations, and comparison between the AML and CHIP results revealed significant overlap between sets of CpG sites associated with DNMT3A or TET2 CHIP and those associated with mutations in the corresponding gene in AML (Fig. 2e, f).